BiotechTube

PF-06473871 + PF-06473871

Phase 2Terminated
0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hypertrophic Scars Resulting From Prior Breast Scar Revision Surgery

Conditions

Hypertrophic Scars Resulting From Prior Breast Scar Revision Surgery

Trial Timeline

Dec 1, 2014 → Jan 1, 2015

NCT ID
NCT02205476

About PF-06473871 + PF-06473871

PF-06473871 + PF-06473871 is a phase 2 stage product being developed by Pfizer for Hypertrophic Scars Resulting From Prior Breast Scar Revision Surgery. The current trial status is terminated. This product is registered under clinical trial identifier NCT02205476. Target conditions include Hypertrophic Scars Resulting From Prior Breast Scar Revision Surgery.

What happened to similar drugs?

3 of 13 similar drugs in Hypertrophic Scars Resulting From Prior Breast Scar Revision Surgery were approved

Approved (3) Terminated (0) Active (10)
✅RanolazineGilead SciencesApproved
✅MavacamtenBristol Myers SquibbApproved
✅MavacamtenBristol Myers SquibbApproved
🔄Mavacamten + PlaceboLianBioPhase 3
🔄Mavacamten + PlaceboBristol Myers SquibbPhase 3
🔄Mavacamten + PlaceboBristol Myers SquibbPhase 3
🔄MavacamtenBristol Myers SquibbPhase 3

Hype Score Breakdown

Clinical
12
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT02205476Phase 2Terminated
NCT01730339Phase 2Completed

Competing Products

20 competing products in Hypertrophic Scars Resulting From Prior Breast Scar Revision Surgery

See all competitors
ProductCompanyStageHype Score
MavacamtenLianBioPhase 1
19
Mavacamten + PlaceboLianBioPhase 3
30
CT-G20 + PlaceboCelltrionPhase 1
21
candesartanAstraZenecaPhase 2
31
LCZ696 + PlaceboNovartisPhase 2
35
Eleclazine + PlaceboGilead SciencesPhase 2/3
30
RanolazineGilead SciencesApproved
43
PF-06473871 + PF-06473871PfizerPhase 2
35
EXC 001 + EXC 001 + EXC 001 + EXC 001PfizerPhase 2
35
MavacamtenBristol Myers SquibbApproved
50
Mavacamten + PlaceboBristol Myers SquibbPhase 3
44
MavacamtenBristol Myers SquibbPre-clinical
30
MavacamtenBristol Myers SquibbPre-clinical
33
MavacamtenBristol Myers SquibbApproved
47
MYK-224Bristol Myers SquibbPhase 2
27
mavacamtenBristol Myers SquibbPhase 2/3
38
mavacamtenBristol Myers SquibbPhase 2
35
MavacamtenBristol Myers SquibbPre-clinical
33
MavacamtenBristol Myers SquibbPre-clinical
30
Mavacamten + PlaceboBristol Myers SquibbPhase 3
40